JP2004525097A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004525097A5 JP2004525097A5 JP2002551010A JP2002551010A JP2004525097A5 JP 2004525097 A5 JP2004525097 A5 JP 2004525097A5 JP 2002551010 A JP2002551010 A JP 2002551010A JP 2002551010 A JP2002551010 A JP 2002551010A JP 2004525097 A5 JP2004525097 A5 JP 2004525097A5
- Authority
- JP
- Japan
- Prior art keywords
- conjugate
- sequence
- glycoprotein
- group
- human erythropoietin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 claims 10
- 101000920686 Homo sapiens Erythropoietin Proteins 0.000 claims 10
- 102000044890 human EPO Human genes 0.000 claims 10
- 102000003886 Glycoproteins Human genes 0.000 claims 7
- 108090000288 Glycoproteins Proteins 0.000 claims 7
- 238000000034 method Methods 0.000 claims 6
- 208000020832 chronic kidney disease Diseases 0.000 claims 4
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims 4
- 230000013595 glycosylation Effects 0.000 claims 4
- 238000006206 glycosylation reaction Methods 0.000 claims 4
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical group [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims 4
- 102000003951 Erythropoietin Human genes 0.000 claims 3
- 108090000394 Erythropoietin Proteins 0.000 claims 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical group OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 3
- 229920001223 polyethylene glycol Polymers 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 230000006337 proteolytic cleavage Effects 0.000 claims 3
- 230000008707 rearrangement Effects 0.000 claims 3
- 208000030507 AIDS Diseases 0.000 claims 2
- 108010092408 Eosinophil Peroxidase Proteins 0.000 claims 2
- 102100031939 Erythropoietin Human genes 0.000 claims 2
- 230000004988 N-glycosylation Effects 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 208000007502 anemia Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 230000004048 modification Effects 0.000 claims 2
- 238000012986 modification Methods 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 238000000746 purification Methods 0.000 claims 2
- 101000958041 Homo sapiens Musculin Proteins 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 230000004071 biological effect Effects 0.000 claims 1
- 210000002798 bone marrow cell Anatomy 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 238000010511 deprotection reaction Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 210000003743 erythrocyte Anatomy 0.000 claims 1
- 238000000855 fermentation Methods 0.000 claims 1
- 230000004151 fermentation Effects 0.000 claims 1
- 102000046949 human MSC Human genes 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000006320 pegylation Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 210000001995 reticulocyte Anatomy 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00127891 | 2000-12-20 | ||
| PCT/EP2001/014434 WO2002049673A2 (en) | 2000-12-20 | 2001-12-08 | Conjugates of erythropoietin (pep) with polyethylene glycol (peg) |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007241171A Division JP4563434B2 (ja) | 2000-12-20 | 2007-09-18 | エリスロポエチンコンジュゲート |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004525097A JP2004525097A (ja) | 2004-08-19 |
| JP2004525097A5 true JP2004525097A5 (https=) | 2005-05-26 |
| JP4656814B2 JP4656814B2 (ja) | 2011-03-23 |
Family
ID=8170728
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002551010A Expired - Lifetime JP4656814B2 (ja) | 2000-12-20 | 2001-12-08 | エリスロポエチンコンジュゲート |
| JP2007241171A Expired - Lifetime JP4563434B2 (ja) | 2000-12-20 | 2007-09-18 | エリスロポエチンコンジュゲート |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007241171A Expired - Lifetime JP4563434B2 (ja) | 2000-12-20 | 2007-09-18 | エリスロポエチンコンジュゲート |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7128913B2 (https=) |
| JP (2) | JP4656814B2 (https=) |
| KR (1) | KR100645843B1 (https=) |
| CN (1) | CN100528235C (https=) |
| AR (1) | AR035407A1 (https=) |
| AU (2) | AU3323002A (https=) |
| BR (1) | BR0116381A (https=) |
| CA (1) | CA2431964C (https=) |
| ES (1) | ES2361824T3 (https=) |
| MX (1) | MXPA03005406A (https=) |
| ZA (1) | ZA200304647B (https=) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT977582E (pt) * | 1997-03-18 | 2002-12-31 | Roche Diagnostics Gmbh | Preparacoes farmaceuticas associadas contendo eritropoietina e preparacoes de ferro |
| US7304150B1 (en) | 1998-10-23 | 2007-12-04 | Amgen Inc. | Methods and compositions for the prevention and treatment of anemia |
| PL219131B1 (pl) | 2000-05-15 | 2015-03-31 | Hoffmann La Roche | Ciekła kompozycja farmaceutyczna, sposób jej wytwarzania oraz jej zastosowanie |
| CA2431964C (en) * | 2000-12-20 | 2013-09-10 | F. Hoffmann-La Roche Ag | Conjugates of erythropoietin (pep) with polyethylene glycol (peg) |
| CZ303658B6 (cs) * | 2001-02-01 | 2013-02-06 | F. Hoffmann-La Roche Ag | Zpusob rekombinantní produkce trypsinu |
| EP1234583A1 (en) * | 2001-02-23 | 2002-08-28 | F. Hoffmann-La Roche Ag | PEG-conjugates of HGF-NK4 |
| US8008252B2 (en) | 2001-10-10 | 2011-08-30 | Novo Nordisk A/S | Factor VII: remodeling and glycoconjugation of Factor VII |
| US7173003B2 (en) | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
| US7214660B2 (en) | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
| US7157277B2 (en) | 2001-11-28 | 2007-01-02 | Neose Technologies, Inc. | Factor VIII remodeling and glycoconjugation of Factor VIII |
| MXPA04012496A (es) | 2002-06-21 | 2005-09-12 | Novo Nordisk Healthcare Ag | Glicoformos del factor vii pegilados. |
| US7459435B2 (en) * | 2002-08-29 | 2008-12-02 | Hoffmann-La Roche Inc. | Treatment of disturbances of iron distribution |
| NZ519011A (en) * | 2002-09-01 | 2005-01-28 | Univ Waikato | Reaction process |
| US7459436B2 (en) * | 2002-11-22 | 2008-12-02 | Hoffmann-La Roche Inc. | Treatment of disturbances of iron distribution |
| KR20060003862A (ko) | 2003-03-14 | 2006-01-11 | 네오스 테크놀로지스, 인크. | 수용성분기폴리머 및 그 접합체 |
| EP2055189A1 (en) | 2003-04-09 | 2009-05-06 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
| US8791070B2 (en) | 2003-04-09 | 2014-07-29 | Novo Nordisk A/S | Glycopegylated factor IX |
| AU2004240553A1 (en) | 2003-05-09 | 2004-12-02 | Neose Technologies, Inc. | Compositions and methods for the preparation of human growth hormone glycosylation mutants |
| JP4266028B2 (ja) | 2003-05-12 | 2009-05-20 | アフィーマックス・インコーポレイテッド | エリスロポエチン受容体に結合する新規ペプチド |
| SI1625156T1 (sl) * | 2003-05-12 | 2013-02-28 | Affymax, Inc. | Peptidi, ki se veĹľejo k eritropoetinskemu receptorju |
| WO2004100997A2 (en) | 2003-05-12 | 2004-11-25 | Affymax, Inc. | Spacer moiety for poly(ethylene glycol) -modified peptides |
| JP2007530440A (ja) * | 2003-05-12 | 2007-11-01 | アフィーマックス・インコーポレイテッド | 新規ポリ（エチレングリコール）修飾化合物およびその用途 |
| WO2005012484A2 (en) | 2003-07-25 | 2005-02-10 | Neose Technologies, Inc. | Antibody-toxin conjugates |
| US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
| US8633157B2 (en) | 2003-11-24 | 2014-01-21 | Novo Nordisk A/S | Glycopegylated erythropoietin |
| ES2445948T3 (es) * | 2003-11-24 | 2014-03-06 | Ratiopharm Gmbh | Eritropoyetina glicopegilada |
| US20060040856A1 (en) | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
| US7956032B2 (en) | 2003-12-03 | 2011-06-07 | Novo Nordisk A/S | Glycopegylated granulocyte colony stimulating factor |
| US7338933B2 (en) | 2004-01-08 | 2008-03-04 | Neose Technologies, Inc. | O-linked glycosylation of peptides |
| WO2006010143A2 (en) | 2004-07-13 | 2006-01-26 | Neose Technologies, Inc. | Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1] |
| WO2006031811A2 (en) | 2004-09-10 | 2006-03-23 | Neose Technologies, Inc. | Glycopegylated interferon alpha |
| US20080176790A1 (en) | 2004-10-29 | 2008-07-24 | Defrees Shawn | Remodeling and Glycopegylation of Fibroblast Growth Factor (Fgf) |
| EA200700990A1 (ru) * | 2004-11-11 | 2008-04-28 | Афимакс, Инк. | Новые пептиды, которые связывают рецептор эритропоэтина |
| WO2006062685A2 (en) * | 2004-11-11 | 2006-06-15 | Affymax, Inc. | Novel peptides that bind to the erythropoietin receptor |
| US9029331B2 (en) | 2005-01-10 | 2015-05-12 | Novo Nordisk A/S | Glycopegylated granulocyte colony stimulating factor |
| EP1848461A2 (en) * | 2005-02-16 | 2007-10-31 | Nektar Therapeutics Al, Corporation | Conjugates of an epo moiety and a polymer |
| US20070154992A1 (en) | 2005-04-08 | 2007-07-05 | Neose Technologies, Inc. | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
| EP1888098A2 (en) | 2005-05-25 | 2008-02-20 | Neose Technologies, Inc. | Glycopegylated erythropoietin formulations |
| EP1891231A4 (en) | 2005-05-25 | 2011-06-22 | Novo Nordisk As | GLYCOPEGYLATED FACTOR IX |
| US8324159B2 (en) * | 2005-06-03 | 2012-12-04 | Affymax, Inc. | Erythropoietin receptor peptide formulations and uses |
| US7550433B2 (en) * | 2005-06-03 | 2009-06-23 | Affymax, Inc. | Erythropoietin receptor peptide formulations and uses |
| US7919461B2 (en) | 2005-06-03 | 2011-04-05 | Affymax, Inc. | Erythropoietin receptor peptide formulations and uses |
| HUE026444T2 (en) * | 2005-08-05 | 2016-05-30 | Araim Pharmaceuticals Inc | Tissue protection peptides and their use |
| US20070105755A1 (en) | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
| AU2006304856A1 (en) * | 2005-10-21 | 2007-04-26 | Synageva Biopharma Corp. | Glycolated and glycosylated poultry derived therapeutic proteins |
| US20080171696A1 (en) * | 2005-10-21 | 2008-07-17 | Avigenics, Inc. | Pharmacodynamically enhanced therapeutic proteins |
| WO2007056191A2 (en) | 2005-11-03 | 2007-05-18 | Neose Technologies, Inc. | Nucleotide sugar purification using membranes |
| ES2516694T3 (es) | 2006-07-21 | 2014-10-31 | Ratiopharm Gmbh | Glicosilación de péptidos a través de secuencias de glicosilación con unión en O |
| WO2008012528A1 (en) | 2006-07-25 | 2008-01-31 | Lipoxen Technologies Limited | N-terminal polysialylation |
| GB0615067D0 (en) * | 2006-07-28 | 2006-09-06 | Ttp Communications Ltd | Reconfigurable signal processing scheme |
| PL2054074T3 (pl) * | 2006-08-04 | 2015-03-31 | Prolong Pharmaceuticals Llc | Zmodyfikowana erytropoetyna |
| US8969532B2 (en) | 2006-10-03 | 2015-03-03 | Novo Nordisk A/S | Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography |
| US20080083154A1 (en) * | 2006-10-05 | 2008-04-10 | Timothy M Gregory | Bait retention fish hook |
| WO2008057537A2 (en) * | 2006-11-08 | 2008-05-15 | Maine Medical Center Research | System and method for identifying erythropoietin-responsive genes |
| TWI782836B (zh) * | 2007-02-02 | 2022-11-01 | 美商艾瑟勒朗法瑪公司 | 衍生自ActRIIB的變體與其用途 |
| KR20100016160A (ko) | 2007-04-03 | 2010-02-12 | 바이오제너릭스 에이지 | 글리코페길화 ｇ―ｃｓｆ를 이용하는 치료 방법 |
| EP2162540A2 (en) | 2007-05-22 | 2010-03-17 | Amgen Inc. | Compositions and methods for producing bioactive fusion proteins |
| WO2008154639A2 (en) | 2007-06-12 | 2008-12-18 | Neose Technologies, Inc. | Improved process for the production of nucleotide sugars |
| US7968811B2 (en) * | 2007-06-29 | 2011-06-28 | Harley-Davidson Motor Company Group, Inc. | Integrated ignition and key switch |
| CL2008002054A1 (es) * | 2007-07-17 | 2009-05-29 | Hoffmann La Roche | Metodo para la regeneracion de una columna de cromatografia de intercambio cationico despues de la elusion de eritropoyetina monopeguilada y metodo para obtener una eritropoyetina monopeguilada, incorporando el metodo de regeneracion de la columna de intercambio cationico. |
| CL2008002053A1 (es) * | 2007-07-17 | 2009-05-22 | Hoffmann La Roche | Metodo para la purificacion de una eritropoyetina monopeguilada (epompeg) que consiste en proporcionar una solucion que contiene eritropoyetina mono, poli y no peguilada y hacerla pasar por dos pasos de cromatografia de intercambio cationico y metodo para producir epo mpeg que incluye metodo de purificacion. |
| US8207112B2 (en) | 2007-08-29 | 2012-06-26 | Biogenerix Ag | Liquid formulation of G-CSF conjugate |
| US8110651B2 (en) | 2008-01-11 | 2012-02-07 | Serina Therapeutics, Inc. | Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same |
| US8101706B2 (en) | 2008-01-11 | 2012-01-24 | Serina Therapeutics, Inc. | Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same |
| KR101582841B1 (ko) | 2008-02-27 | 2016-01-11 | 노보 노르디스크 에이/에스 | 콘쥬게이트된 인자 ｖｉｉｉ 분자 |
| WO2015032973A1 (en) * | 2013-09-09 | 2015-03-12 | Lek Pharmaceuticals D.D. | Erythropoietin compositions for oral administration |
| WO2015130963A2 (en) | 2014-02-27 | 2015-09-03 | Xenetic Biosciences, Inc. | Compositions and methods for administering insulin or insulin-like protein to the brain |
| SG11201802180TA (en) * | 2015-09-18 | 2018-04-27 | Univ Miyazaki | Long-acting adrenomedullin derivative |
| WO2018197545A1 (en) | 2017-04-25 | 2018-11-01 | Lipoxen Technologies Limited | Methods of treating multiple myeloma cancers expressing high levels of epo-receptor using psa-epo |
| US20240424017A1 (en) * | 2023-06-23 | 2024-12-26 | The Government Of The United States Of America, As Represented By The Secretary Of The Navy | Nanoparticle (np)-enhanced expression of aquaporin-4 channels and water transport in human astrocytes |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR850004274A (ko) * | 1983-12-13 | 1985-07-11 | 원본미기재 | 에리트로포이에틴의 제조방법 |
| NZ210501A (en) | 1983-12-13 | 1991-08-27 | Kirin Amgen Inc | Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence |
| IL77081A (en) | 1984-12-04 | 1999-10-28 | Genetics Inst | Dna sequence encoding human erythropoietin process for the preparation thereof and a pharmaceutical composition of human erythropoietin |
| US4677195A (en) | 1985-01-11 | 1987-06-30 | Genetics Institute, Inc. | Method for the purification of erythropoietin and erythropoietin compositions |
| EP0248656B1 (en) | 1986-06-04 | 1993-03-31 | Director-General of the Agency of Industrial Science and Technology | Composition for cell cultivation and use thereof |
| DE3787805T2 (de) | 1986-08-04 | 1994-02-10 | Garvan Inst Med Res | Serumfreies gewebekulturmedium, das ein polymerzellenschutzmittel enthält. |
| US4954437A (en) | 1986-09-15 | 1990-09-04 | Integrated Genetics, Inc. | Cell encoding recombinant human erythropoietin |
| IL87737A (en) | 1987-09-11 | 1993-08-18 | Genentech Inc | Method for culturing polypeptide factor dependent vertebrate recombinant cells |
| EP0343635B1 (en) | 1988-05-25 | 1994-08-24 | Teijin Limited | Process for continuously culturing adherent animal cells |
| FR2646438B1 (fr) | 1989-03-20 | 2007-11-02 | Pasteur Institut | Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration |
| ATE174058T1 (de) * | 1989-11-06 | 1998-12-15 | Cell Genesys Inc | Herstellung von proteinen mittels homologer rekombination |
| US5272071A (en) * | 1989-12-22 | 1993-12-21 | Applied Research Systems Ars Holding N.V. | Method for the modification of the expression characteristics of an endogenous gene of a given cell line |
| GB9022545D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Culture medium |
| DE4115722A1 (de) | 1991-05-14 | 1992-11-19 | Boehringer Mannheim Gmbh | Serumfreies medium zur kultivierung von saeugerzellen |
| US5641670A (en) * | 1991-11-05 | 1997-06-24 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
| US5733761A (en) * | 1991-11-05 | 1998-03-31 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
| AU673190B2 (en) | 1992-07-13 | 1996-10-31 | Bionebraska, Inc. | Method for modification of recombinant polypeptides |
| NZ250375A (en) | 1992-12-09 | 1995-07-26 | Ortho Pharma Corp | Peg hydrazone and peg oxime linkage forming reagents and protein derivatives |
| CN1057534C (zh) | 1993-08-17 | 2000-10-18 | 柯瑞英-艾格公司 | 促红细胞生成素类似物 |
| JPH07165789A (ja) * | 1993-12-15 | 1995-06-27 | Toray Res Center:Kk | タンパク質のアミノ末端ペプチドの分離方法 |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| WO1996041813A2 (en) | 1994-11-09 | 1996-12-27 | Offord Robin E | Functionalized polymers for site-specific attachment |
| IL118201A (en) | 1995-05-11 | 2004-12-15 | Roche Diagnostics Gmbh | Preparation comprising a protein with human erythropoietin activity which is free of serum and non-recombinant mammalian protein and process for the preparation thereof |
| US5672662A (en) * | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
| DE19535571A1 (de) | 1995-09-14 | 1997-03-20 | Boehringer Mannheim Gmbh | Pharmazeutische Kombinationspräparate und deren Verwendung zur Behandlung von Hämodialysepatienten |
| TW518219B (en) | 1996-04-26 | 2003-01-21 | Chugai Pharmaceutical Co Ltd | Erythropoietin solution preparation |
| EP1731174A3 (en) | 1996-08-02 | 2007-01-17 | Ortho-McNeil Pharmaceutical, Inc. | Polypeptides having a covalently bound N-terminal polyethylene glycol via hydrazone or oxime bond |
| DE69800640T2 (de) | 1997-01-29 | 2001-07-05 | Polymasc Pharmaceuticals Plc, London | Pegylationsverfahren |
| EP0885613A1 (de) | 1997-06-21 | 1998-12-23 | Roche Diagnostics GmbH | Verwendung von modifizierten Hämoglobinen zur Behandlung von Anämien und Kombinationspräparate umfassend Erythropoietin und modifiziertes Hämoglobin |
| GB9716790D0 (en) * | 1997-08-07 | 1997-10-15 | Creative Peptides Sweden Ab | Recombinant DNA molecules comprising multimeric copies of a gene sequence and expression thereof |
| DE19734293A1 (de) | 1997-08-08 | 1999-02-11 | Boehringer Mannheim Gmbh | Verwendung von pharmazeutischen Kombinationspräparaten enthaltend Erythropoietin und Eisenpräparate zur Behandlung von rheumatischen Erkrankungen |
| WO2000032772A2 (en) * | 1998-11-30 | 2000-06-08 | Eli Lilly And Company | Erythropoietic compounds |
| BR122013003013B8 (pt) * | 1999-01-14 | 2021-07-06 | Bolder Biotechnology Inc | proteína isolada monopeguilada do hormônio do crescimento e método para sua obtenção |
| JO2291B1 (en) | 1999-07-02 | 2005-09-12 | اف . هوفمان لاروش ايه جي | Erythropoietin derivatives |
| CZ299516B6 (cs) * | 1999-07-02 | 2008-08-20 | F. Hoffmann-La Roche Ag | Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem |
| PL219131B1 (pl) | 2000-05-15 | 2015-03-31 | Hoffmann La Roche | Ciekła kompozycja farmaceutyczna, sposób jej wytwarzania oraz jej zastosowanie |
| CA2431964C (en) * | 2000-12-20 | 2013-09-10 | F. Hoffmann-La Roche Ag | Conjugates of erythropoietin (pep) with polyethylene glycol (peg) |
-
2001
- 2001-12-08 CA CA2431964A patent/CA2431964C/en not_active Expired - Lifetime
- 2001-12-08 MX MXPA03005406A patent/MXPA03005406A/es active IP Right Grant
- 2001-12-08 CN CNB018206093A patent/CN100528235C/zh not_active Expired - Lifetime
- 2001-12-08 ES ES01984811T patent/ES2361824T3/es not_active Expired - Lifetime
- 2001-12-08 KR KR1020037008299A patent/KR100645843B1/ko not_active Expired - Fee Related
- 2001-12-08 AU AU3323002A patent/AU3323002A/xx active Pending
- 2001-12-08 AU AU2002233230A patent/AU2002233230B2/en not_active Ceased
- 2001-12-08 JP JP2002551010A patent/JP4656814B2/ja not_active Expired - Lifetime
- 2001-12-08 BR BR0116381-7A patent/BR0116381A/pt not_active IP Right Cessation
- 2001-12-11 US US10/014,363 patent/US7128913B2/en not_active Expired - Lifetime
- 2001-12-18 AR ARP010105862A patent/AR035407A1/es unknown
-
2003
- 2003-06-13 ZA ZA200304647A patent/ZA200304647B/en unknown
-
2007
- 2007-09-18 JP JP2007241171A patent/JP4563434B2/ja not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004525097A5 (https=) | ||
| TWI364295B (en) | Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity | |
| KR101160611B1 (ko) | 폴리(에틸렌 글리콜)로 변형된 펩티드 기재 화합물용 신규 스페이서 부분 | |
| JP4067058B2 (ja) | Ｐｅｇ化ｈｇｆ | |
| JP2005509609A5 (https=) | ||
| RU2305554C2 (ru) | Применение эритропоэтина | |
| CA2408685A1 (en) | Liquid pharmaceutical composition containing an erythropoietin derivate | |
| JP2006512326A (ja) | 心臓疾患におけるエリスロポエチンの新規な使用 | |
| HU226233B1 (en) | Erythropoietin derivatives | |
| JP2000508356A (ja) | 改良型インターフェロン−ポリマーコンジュゲート | |
| JP2003503464A (ja) | ポリエチレングリコールを有するエリスロポエチン接合体 | |
| EP1037657A4 (en) | ALPHA INTERFERON-POLYMER CONJUGATES WITH INCREASED BIOLOGICAL EFFECTIVENESS AND METHOD FOR THE PRODUCTION THEREOF | |
| JP2012067100A (ja) | Ｉｌ−２１の誘導体 | |
| JPWO1996028475A1 (ja) | Ｐｅｇ化ｈｇｆ | |
| RU2293574C2 (ru) | Содержащие пэг конъюгаты hgf-nk4 | |
| EP0726778A1 (en) | Oral delivery of chemically modified proteins | |
| US20070166278A1 (en) | Novel g-csf conjugates | |
| RU2010106430A (ru) | Интерферон альфа 2в, модифицированный полиэтиленгликолем, получение препарата и его применение | |
| WO2013138730A1 (en) | Polymeric conjugates of c1-inhibitors | |
| CN102421447A (zh) | 用peg标记干扰素的方法 | |
| WO2005058347A1 (en) | Use of erythropoietin in the treatment of disturbances of iron distribution in chronic inflammatory intestinal diseases | |
| US20060083715A1 (en) | Interferon beta-like molecules for treatment of stroke | |
| RU2575796C2 (ru) | Пегилированный конъюгат варианта рекомбинантного консенсусного интерферона и способ его получения, и применение | |
| RU2575796C9 (ru) | Пегилированный конъюгат варианта рекомбинантного консенсусного интерферона и способ его получения, и применение | |
| KR100694994B1 (ko) | 사람 과립구 콜로니 형성인자 동종체 |